Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin

Launched by ATEA PHARMACEUTICALS, INC. · Apr 3, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how the study drug Bemnifosbuvir/Ruzasvir (BEM/RZR) interacts with two other medications: Digoxin and Rosuvastatin. The goal is to understand if taking these medications together affects how well they work or causes any side effects. This study will involve healthy volunteers, and it is currently not open for recruitment.

To be eligible for the trial, participants should be between 18 and 65 years old, weigh at least 50 kg, and have a body mass index (BMI) between 18 and 30. They also need to agree to use two forms of birth control during the study and for 90 days afterward. However, people with certain health conditions, those who have recently used other drugs, or who are taking prescription medications may not qualify. Participants can expect to follow specific study rules and provide informed consent, meaning they will be fully aware of what the study involves before agreeing to take part.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug.
• • Minimum body weight of 50 kg and body mass index (BMI) of 18-30 kg/m2.
• • Willing to comply with the study requirements and to provide written informed consent.
• Exclusion Criteria:
• • Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2.
• • Abuse of alcohol or drugs.
• • Use of other investigational drugs within 28 days of dosing.
• • Concomitant use of prescription medications, or systemic over-the-counter medications.
• • Other clinically significant medical conditions or laboratory abnormalities.